Literature DB >> 29869116

Treating the idiopathic nephrotic syndrome: are steroids the answer?

Georges Deschênes1, Claire Dossier2, Julien Hogan2.   

Abstract

The use of steroids in idiopathic nephrotic syndrome is the major discovery of the twentieth century in the field of pediatric nephrology. At onset of the twenty-first century, steroids remain the first line of treatment at first flare. All the protocols to treat the first flare are similar by a common sequence including a first phase of daily prednisolone/prednisone at a dose of 60 mg/m2/day for at least 4 weeks followed by an alternate-day regimen for several weeks. It appears that a cumulated dose of 2240 mg/m2 given in 8 weeks at the first flare without tapering sequence is not inferior to increased dose and duration in terms of prevalence of frequent relapsers and the subsequent cumulated dose of steroids at 24 months of follow-up. A higher cumulated dose might only be interesting in patients aged below 4 years although a formal demonstration is still missing. Several retrospective studies are concordant to suggest that intravenous methylprednisolone pulses are useful to reach a full urinary remission in case of oral resistance to 4 weeks of oral prednisone/prednisolone. A majority of patients have multiple relapses after the treatment of the first flare and half meet the definition of steroid dependency. In those patients, long-lasting alternate-day prednisone/prednisolone therapy does not lead to long-lasting remission, opening the question of the best strategy of immunosuppression.

Entities:  

Keywords:  Intravenous methylprednisolone; Prednisolone; Prednisone; Steroid dependency; Steroid resistance

Mesh:

Substances:

Year:  2018        PMID: 29869116     DOI: 10.1007/s00467-018-3963-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  55 in total

1.  Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome.

Authors:  Jacob Simmonds; Nicholas Grundy; Richard Trompeter; Kjell Tullus
Journal:  Arch Dis Child       Date:  2010-02       Impact factor: 3.791

Review 2.  Corticosteroid therapy for nephrotic syndrome in children.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Narelle S Willis; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2015-03-18

3.  Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis.

Authors:  Ihab Mahmoud; Fathi Basuni; Alaa Sabry; Amr El-Husseini; Nabil Hassan; Nagy Sayed Ahmad; Mahmoud Elbaz; Fatma Moustafa; Mohamed Sobh
Journal:  Nephrol Dial Transplant       Date:  2005-04       Impact factor: 5.992

4.  Growth in boys with idiopathic nephrotic syndrome on long-term cyclosporin and steroid treatment.

Authors:  Valérie Leroy; Véronique Baudouin; Corinne Alberti; Geneviève Guest; Patrick Niaudet; Chantal Loirat; Georges Deschenes; Paul Czernichow; Dominique Simon
Journal:  Pediatr Nephrol       Date:  2009-08-11       Impact factor: 3.714

5.  Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome.

Authors:  Pankaj Hari; Arvind Bagga; Mukta Mantan
Journal:  Indian Pediatr       Date:  2004-10       Impact factor: 1.411

6.  A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome.

Authors:  M Broyer; F Terzi; A Lehnert; M F Gagnadoux; G Guest; P Niaudet
Journal:  Pediatr Nephrol       Date:  1997-08       Impact factor: 3.714

7.  Cyclophosphamide in steroid-dependent nephrotic syndrome.

Authors:  Sonia Azib; Marie Alice Macher; Theresa Kwon; Agnes Dechartres; Corinne Alberti; Chantal Loirat; Georges Deschênes; Véronique Baudouin
Journal:  Pediatr Nephrol       Date:  2011-03-12       Impact factor: 3.714

8.  Behavioural abnormalities in children with new-onset nephrotic syndrome receiving corticosteroid therapy: results of a prospective longitudinal study.

Authors:  Aishvarya Upadhyay; Om P Mishra; Rajniti Prasad; Shashi K Upadhyay; Franz Schaefer
Journal:  Pediatr Nephrol       Date:  2015-09-28       Impact factor: 3.714

9.  Deflazacort Versus Prednisolone: Randomized Controlled Trial in Treatment of Children With Idiopathic Nephrotic Syndrome.

Authors:  Ravish Singhal; Sadbhavna Pandit; Neeraj Dhawan
Journal:  Iran J Pediatr       Date:  2015-04-18       Impact factor: 0.364

10.  Ocular implications of long-term prednisone therapy in children.

Authors:  L D Kaye; J W Kalenak; R L Price; R Cunningham
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1993 May-Jun       Impact factor: 1.402

View more
  4 in total

1.  Effects of miR-151-3p-mediated GLCCl1 expression on biological function in children with nephrotic syndrome.

Authors:  Chengliang Xu; Yanping Li
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 2.  Treatment of nephrotic syndrome: going beyond immunosuppressive therapy.

Authors:  Jinghong Zhao; Zhihong Liu
Journal:  Pediatr Nephrol       Date:  2019-03-23       Impact factor: 3.714

3.  Long-term obesity prevalence and linear growth in children with idiopathic nephrotic syndrome: is normal growth and weight control possible with steroid-sparing drugs and low-dose steroids for relapses?

Authors:  Nilüfer Göknar; Hazel Webb; Aoife Waters; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2021-11-12       Impact factor: 3.651

Review 4.  Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome.

Authors:  Martin T Christian; Andrew P Maxted
Journal:  Pediatr Nephrol       Date:  2021-02-20       Impact factor: 3.651

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.